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Abstract: BACKGROUND: HIV/AIDS-Associated Lipodystrophy Syndrome includes changes in body fat distribu-
tion, with or without metabolic changes. The loss of fat from the face, called facial lipoatrophy, is one of the most
stigmatizing signs of the syndrome. 
OBJECTIVES: To evaluate the effect of FL treatment using polymethylmethacrylate (PMMA) implants on disease
progression, assessed by viral load and CD4 cell count. 
METHODS: This was a prospective study of 44 patients treated from July 2009 to December 2010. Male and female
patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the
study. PMMA implantation was done to fill atrophic areas. Laboratory tests were conducted to measure viral
load and CD4 count before and after treatment. 
RESULTS: Of the 44 patients, 72.72% were male and 27.27% female, mean age of 44.38 years. Before treatment, 82%
of patients had undetectable viral load, which increased to 88.6% after treatment, but without statistical signifi-
cance (p = 0.67). CD4 count before treatment ranged from 209 to 1293, averaging 493.97. After treatment, the aver-
age increased to 548.61. The increase in CD4 count after treatment was statistically significant with p = 0.02. 
CONCLUSION: The treatment of FL with PMMA implants showed a statistically significant increase in CD4 count
after treatment, revealing the impact of FL treatment on disease progression. Viral load before and after treatment
did not vary significantly. 
Keywords: CD4-Positive T-Lymphocytes; HIV; HIV-Associated lipodystrophy syndrome; Polymethyl methacry-
late; Viral load
Resumo: FUNDAMENTOS: A Síndrome Lipodistrófica Associada ao HIV/AIDS compreende alterações na dis-
tribuição da gordura corporal, acompanhada ou não de alterações metabólicas. A perda da gordura facial,
chamada lipoatrofia facial, é dos sinais mais estigmatizantes da síndrome. 
Objetivos: Avaliar o impacto do tratamento dalipoatrofia facial com implante de polimetilmetacrilato sobre a pro-
gressão da doença, avaliada pela contagem da carga viral e a contagem de células CD4. 
Métodos: Estudo prospectivlipoatrofia facial clinicamente detectável e sem tratamento prévio. Foi realizado
implante de polimetilmetacrilato para preenchimento das áreas atróficas. Foram realizadas contagem da carga
viral e células CD4 antes e após o tratamento. 
Resultados: Dos 44 pacientes, 72,72% eram do sexo masculino e 27,27% do feminino, e idade média de 44,38 anos.
Antes do tratamento, 82% dos pacientes apresentavam carga viral indetectável, que aumentou para 88,6% após
o tratamento, mas sem significância estatística (p=0,67). A contagem de CD4 antes do implante variou de 209 a
1293, com média de 493,97. Após o tratamento, essa média aumentou para 548,61. O aumento do CD4 após o
tratamento foi estatisticamente significativo, com p=0,02. 
Conclusão: O tratamento dalipoatrofia facial com implante de polimetilmetacrilato levou ao aumento estatistica-
mente significativo da contagem de CD4, mostrando impacto do tratamento da LF sobre a evolução da doença.
A carga viral antes e após tratamento não variou de maneira estatisticamente significativa.
Palavras-chave: Carga viral; HIV; Linfócitos T CD4-Positivos; Polimetilmetacrilato; Síndrome de lipodistrofiaas-
sociada ao HIV
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INTRODUCTION
Since 1996, new anatomic and metabolic
changes have been described in patients with
HIV/AIDS, particularly in those undergoing anti-
retroviral therapy. Patients presented with peripheral
fat atrophy and central fat accumulation, accompa-
nied by insulin resistance and several abnormalities in
serum lipids.1 These changes were later described as
lipodystrophy and/or HIV-associated lipodystrophy
syndrome (HIVLS).
Other anatomical changes include lipoatrophy
of the face, upper and lower limbs and prominence of
superficial veins, associated or not with accumulation
of fat in the abdomen, neck and breasts. Metabolic
changes include lipid alterations and abnormal glu-
cose homeostasis, which may or may not be associat-
ed with body fat changes.2
The prevalence of lipodystrophy described in
the literature varies widely; some articles describe
rates of 7-84% among HIV/AIDS patients, in use or
not of antiretrovirals.3-6
Given the difficulty to assess face fat (FL), the
method most widely used to diagnose facial lipoatro-
phy includes a subjective description of changes in
subcutaneous fat by the patient and the physician’s
clinical observation.7
The exact mechanism that leads to the develop-
ment of anatomic and metabolic changes is still
unclear. Mitochondrial toxicity associated with the
use of nucleoside reverse-transcriptase inhibitors
(NRTIs), deregulation of tumor necrosis factor α
(TNF), inhibition of cytochrome P450 associated with
protease inhibitors, local effect of HIV on cortisol pro-
duction and other changes in steroid hormone levels
have been described, among others. None of these
hypotheses explain all aspects of the changes caused
by the syndrome individually. The disease probably
has a multifactorial cause.8
Although fat loss is also visible in the arms, legs
and buttocks, the face is the region where it is most
evident and impactful.7
Facial lipoatrophy consists of a progressive loss
of facial fat, mainly due to decreased malar fat (Bichat
fat pad) and temporal fat. As a consequence, new skin
furrows develop and skin depressions and lines of
expression become more prominent. This can result in
a skeletal appearance. All this leads to wrinkling of
the face and gives the individual an aged appearance.9
Furthermore, an emaciated and haggard face has
brought back the old stigma of AIDS and fear of an
involuntary and unintentional disclosure of an HIV
status.10
As the symptoms worsen, many patients begin
to show the typical characteristics of lipodystrophy
syndrome, bringing back the stigma of AIDS and the
need for specialists working with HIV/AIDS patients
to identify these changes and seek treatment
options.8,11
Changes in body image can be extremely dis-
turbing in terms of psychosocial well-being, increas-
ing the stigma of the disease. 
Patients have described FL as a visible marker
that identifies HIV carriers; it is perceived as the “face
of AIDS,” or the “Kaposi’s sarcoma of the 21
st
centu-
ry”. It also causes problems in social and family rela-
tionships, leading to the isolation of patients. One of
the major consequences of FL is treatment withdraw-
al due to the psychosocial effects of body fat redistri-
bution.2
Given the prevalence of changes in fat redistrib-
ution, it is clear that HIV-associated facial lipoatrophy
is becoming epidemic. It stigmatizes those affected
causing a major impact on these patients’ quality of life.
These patients often show good disease control and are
healthy, but their facial features suggest otherwise, and
the psychological effects are often devastating.12
Patients with FL are exposed and cannot hide
their condition. This can result in discrimination at
work, it can affect relationships, sexual function and
even adherence to treatment. This affects these
patients’ sense of well-being, as well as their body
image and self-esteem. In some cases, patients become
socially isolated.13
Disorders of body fat distribution associated
with antiretroviral therapy are now considered irre-
versible and there are no therapeutic strategies that
allow sufficient recovery of adipose tissue for a consis-
tent clinical perception, as described in several studies.
Cutaneous implants are an important therapeu-
tic option, with high levels of patient satisfaction.14,15
Among the fillers available on the market, poly-
methylmethacrylate (PMMA) is the material used to
treat FL in the Unified Health System (SUS).
Considering the sometimes devastating effect
of FL on the lives of patients, treatment leads to posi-
tive effects on their mental, emotional and social con-
dition. Studies in the literature have shown improved
self-esteem, interpersonal relationships and quality of
life of patients undergoing treatment with various
filler implants.14 There is also a report of improvement
of depression in patients with AIDS treated with poly-
lactic acid implants.16
However, there is no report about whether
treatment of FL has an effect on the progression of
HIV/AIDS.
The most accurate and widely used markers of
HIV/AIDS infection are CD4 count and plasma viral
load, which serve as reliable measures of disease pro-
gression.17
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The objective of this study was to evaluate the
effect of FL treatment using subcutaneous implants or
supraperiosteal PMMA on the progression of
HIV/AIDS, as assessed by quantification of viral load
and CD4 count before and after treatment.
METHODS
We conducted a prospective, experimental,
descriptive-analytical study of 44 patients seen at the
Facial Lipodystrophy Outpatient Service at Hospital
Regional da Asa Norte – HRAN, State Department of
Health of the Federal District - SES / DF from July
2009 to December 2010.
All patients were referred by infectious disease
specialists working in the health network of the
Federal District through a standard form filled with
laboratory and clinical data attesting the good general
health of the patients for them to undergo FL treat-
ment.
Inclusion criteria were HIV-positive patients,
antiretroviral users or not, 18 years old or older, of
both sexes and with clinically detectable FL. Clinical
assessment considered the medical report and the
patients’ reports on the loss of face fat. On clinical
examination, the presence of lipoatrophy in the malar
and/or zygomatic and/or pre-auricular and/or tem-
poral regions was evaluated, as well as aggravation of
furrows and/or visualization of temporal vessels.
Patients undergoing ARV therapy should do it regu-
larly throughout the treatment. The therapeutic regi-
men adopted should have been initiated at least six
months before the start of the study. There could have
been no changes to this regimen during this period.
Patients undergoing changes in the treatment regimen
or who initiated ARV use during the study were
excluded.
Patients expressed the desire to undergo treat-
ment with PMMA implants and agreed to participate
in the study by signing the informed consent form.
All patients had their plasma viral load and
CD4 count measured three months before and six
months after treatment. The measurement of viral
load and CD4 count before and after the implant was
done in the same laboratory and the same standard
laboratory techniques were used. 
The areas to be filled were marked with the
patient in the sitting position. Patients were then
accommodated in chairs for a backrest tilted proce-
dure.
Asepsis was done with gauze soaked in 70%
ethanol and topical anesthesia was done with 4% lido-
caine applied to the area to be treated 30 minutes
before the procedure. In patients with a lower pain
threshold, regional nerve block anesthesia was done
(mentonian and infraorbital nerves).
The filler used was polymethylmethacrylate
(Metacryll), produced and marketed by Nutricel. The
PMMA used was provided by the program
STD/AIDS in accordance with Ordinance 2582/GM
of December 2, 2004.
The concentration of the PMMA used was 10%
for treatment of the temporal region and 30% for treat-
ment of other areas. The application technique used
was retro injection with previous aspiration. The
material was subcutaneously or supraperiosteally
injected, in a parallel and cross-fanning manner, to
obtain satisfactory filling of the areas marked.
Hemostasis was achieved with local compression.
After the procedure, all patients were oriented to
apply ice to the area treated, not to expose it to heat
sources, not to practice physical activities, not to drink
alcohol and avoid sun exposure for 7 days, as well as
massage the areas treated. Paracetamol was pre-
scribed in case of pain. As many sessions as necessary
were done to complement the implant, with a 30-day
interval in between sessions.
We compared plasma viral load and CD4 count
obtained before and after treatment.
The statistical test used was Wilcoxon test.
RESULTS
Of the 44 patients studied, 32 (72.72%) were
male and 12 (27.27%) female, with a male/ female
ratio of 2.66.
The average age of the patients was 44.38 years,
with the youngest patient being 34 years old and the
oldest, 62 years old.
Before treatment, 82% (N = 36) of the respon-
dents had a mean viral load of up to 50 viral
copies/ml of blood. The highest viral load prior to
treatment was 31,300 copies/ml of blood. After treat-
ment, the percentage of patients with viral load below
50 viral copies/ml of blood increased to 88.6% (N =
39). Despite the increased percentage of patients with
undetectable viral load, this increase was not statisti-
cally significant, with p = 0.67. After treatment, the
highest viral load detected was 122,694 copies/ml of
blood. (Tables 1 and 2)
The mean CD4 count before treatment was
493.97. The highest value observed was 1293 and the
lowest, 209. After treatment, the mean CD4 count
increased to 548.61, and the maximum value found
was 1485 and the minimum was 118 (Tables 3, 4 and
Graph 1). This increase in CD4 count was statistically
significant, with p = 0.02. 
The highest increase found in CD4 count was
that of a patient who had 581 cells/mm 3 before treat-
ment and 1485 cells/mm 3 after treatment (Figures 1
and 2).
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Viral load Total %
Up to 50 36 82
Greater than 50 8 18
Total 44 100
TABLE 1: Viral load prior to treatment 
(number of viral copies /ml blood)
Viral load Total %
Up to 50 39 89
Greater than 50 5 11
Total 44 100
TABLE 2: Viral load after treatment 
(number of viral copies / ml blood)
Range Frequency
100-199 0
200-299 9
300-399 4
400-499 15
500-599 5
600-699 3
over 700 8
TABLE 3: Distribution of CD4 count (cells / mm3) 
per range before treatment
Range Frequency
100-199 1
200-299 3
300-399 10
400-499 5
500-599 9
600-699 9
over 700 7
TABLE 4: Distribution of CD4 count (cells / mm3) 
per range after treatment
Fr
eq
u
en
cy
Graph 1: Distribution of patients by CD4 range before and after treatment
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DISCUSSION
Patients in this study were evaluated in relation
to HIV/AIDS by measurements of viral load and CD4
count 3 months before treatment and 6 months after
treatment.
The markers used for assessment of disease
progression were CD4 count and plasma viral load,
which are the most accurate and widely used in
HIV/AIDS infection.17
There is a well-established relationship
between the number of circulating CD4+ lymphocytes
and susceptibility to infection. Response to antiretro-
viral therapy, as measured by CD4 + count and HIV
viral load, is associated with slower disease progres-
sion and reduced incidence of death. Studies have
also shown that the greatest reductions in viral load
are associated with greater improvements in clinical
outcome. Even modest reductions of HIV RNA in the
plasma are associated with reduced risk of subsequent
opportunistic infections.18
Before treatment of FL, the average CD4 +
count of study patients was 493.97 and 82% of patients
had undetectable viral load. Skeie et al. showed that
patients in their study also had well-controlled HIV
infection with an average CD4 of 520 cells/microliter,
with a variation of more or less 320 cells, and 70% had
a viral load of 50 viral copies/ml.15
This study showed an increase in the percent-
age of patients with undetectable viral load, that is,
less than 50 viral copies per ml of blood, which
increased from 82% before treatment to 88.6% after
treatment. However, this increase was not significant.
The increase in CD4 count after treatment was
statistically significant. This is something new in the
literature, as no study that was carried out in the last
20 years and that evaluated and proved the effect of
FL treatment on CD4 count was found, at the time this
study was conducted, in the MEDLINE and PubMed
databases.
Considering that plasma levels of HIV -1
ribonucleic acid (RNA) and CD4 + lymphocyte count
are the most important variables that determine the
rate of progression of AIDS19 and the well-established
relationship between the number of circulating CD4 +
lymphocytes and susceptibility to infection, the
importance of this finding becomes evident, as it can
reveal the influence of FL treatment on the progres-
sion of HIV/AIDS.18
This finding may reflect the influence of the
psychological condition of patients as a determiner of
their immune status. Improved self-esteem and better
quality of life of patients treated with cutaneous
implants have been reported.15,16
Ironson et al. suggest that viral load is more
sensitive to psychological influences than CD4
count.20 However, in the present study, the significant
variation found, which is sometimes attributed to the
psychological impact of the treatment, refers exclu-
sively to CD4 count.
Several studies have demonstrated the influ-
ence of psychological factors on the immune system.
Depression has been involved in a faster decline of
CD4 cells as well as progression to AIDS and death.20
Similarly, stress has also been involved in the decline
of CD4 cells and progression to AIDS.20
A historical breakthrough in the knowledge
about the influence of the psychological state on
FIGURE 1: Patient
before treatment of
FL with PMMA
implant. The
patient had a CD4
count of 581
cells/mm3
FIGURE 2: The same
patient after
PMMA implanta-
tion. Six months
after the end of
treatment, the
patient presented a
CD4 count of 1485
cells /mm3, the
highest increase
observed in this
study
575 Soares FMG, Costa IMC
immunity was a publication by Soloman in 1964.
Since then, studies about how behavior and emotions
can modulate the immune system have become more
frequent. Laboratory findings have shown transient
immune changes in the conditions of acute stress. One
possibility is the acute secretion of hormones respon-
sive to stress, particularly catecholamines, which can
change a number of aspects of the immune system,
such as the distribution of some cell subpopulations in
peripheral blood circulation.21
Stress factors resistant to changes in behavior,
especially those considered unpredictable or uncon-
trollable, can be continuously associated with elevat-
ed stress-responsive hormones, even after repeated
exposure. This condition leads to deregulation of the
endocrine and immune systems, as well as changes in
health status, in response to vaccines and wound heal-
ing.21 Some factors of chronic stress that have already
been identified are isolation and exposure to harsh
environments. These situations are sometimes present
in the life of patients with HIV/AIDS, especially when
they are FL carriers.21
Mood swings are also related to changes in the
immune system. A negative mood is associated with
reduced natural killer cells (NK) in women.21 HIV
patients with a positive attitude about their health
showed a slower immune decline, later establishment
of symptoms and longer survival.21
In HIV patients, a more rapid progression of the
disease has been associated with stressful events and
less cumulative social support.21 These patients may
experience psychological responses to stressors that
may contribute to immune deficiency.22
The association between immunological func-
tion and personal relationships is one of the most
robust findings of neuropsychoimmunology. The
activity of NK cells and proliferative response of
peripheral blood leukocytes to mitogenic stimuli were
associated with groups who had greater social sup-
port.21 Likewise, individuals with greater social sup-
port respond better to the vaccine against the hepati-
tis B virus. Individuals with fewer social ties are more
susceptible to respiratory viruses. The presence of
anxiety/anguish and poorer interpersonal relation-
ships seemed to be related with a negative regulation
of the immune system in a series of studies.21
One of the greatest impacts of FL is on the social
relations of the patient. Rejection and isolation add to
the stress of possible disease disclosure. The feeling of
rejection has been associated with changes in periph-
eral leukocyte cell count and deregulation of the
immune response.21
Improvement in the social relations of the
patients may contribute to enhance the immune system. 
Studies show that close relationships, such as
marriage, which are chronically abrasive or stressful,
may lead to persistent deregulation of the immune
system.21
Neuropsychological interventions have also
shown a positive impact on the immune system, such
as stress management through cognitive behavioral
therapy.21 Usually, mourning causes a reduction in
CD4 cells and increased markers of lymphocyte acti-
vation. Cognitive therapy upon the death of a close
friend or partner due to the disease may be associated
with a slower decline of CD4 cells.21
In a study of HIV-positive patients who were
subjected to 10 weeks of cognitive therapy for stress
management, they showed signs of immune system
reconstitution after 6 to 12 months of follow-up.22
Stress reduction seemed related to the ability of the
immune system to reconstitute T cells, possibly affect-
ing the cellular immune response to antigens and pro-
tecting against opportunistic diseases.22 The habit of
writing about emotions led to an increase in CD4 cells,
but without changes in viral load.23 This and other
studies are in agreement with the results of the pres-
ent study regarding the significant effect that psycho-
logical factors have on the course of HIV infection.
Stress changes the immune function and affects
different populations of immune cells in different
ways, improving the responses of monocytes or
depressing that of lymphocytes.24 The most frequently
reported consequence of stress and depression has
been suppression of the immune response.24
Since the description of the “general adaptation
syndrome”, the fundamental concepts about stress
began to be clarified. As the syndrome could be
caused by physical or psychological stimuli, it was
natural to assume that the endocrine and central nerv-
ous system interacted in response to stress.25
It is known today that stimuli from the central
nervous system can modulate an immune response.
The endocrine system is responsible for many of the
associations between the two systems.25
The endocrine system acts as the access gate to
the psychological influences on health. Stress and
depression can cause the release of pituitary and adre-
nal hormones that have multiple actions on the
immune system. Social stress can thus increase cate-
cholamines and cortisol.21 Stress, via secretion of glu-
cocorticoids, alters the TH1/TH2 balance, favoring
the TH2 immune response. As a consequence, there is
a decrease in the cellular immune response and an
increase in the humoral response.25 In addition, dis-
tressed individuals often adopt multiple risky behav-
iors, such as poor nutrition and inadequate sleep, they
are more likely to abuse alcohol and other drugs, and
An Bras Dermatol. 2013;88(4):570-7.
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they practice less physical activities. All these behav-
iors also lead to endocrine and immunological conse-
quences.21
The sympathetic nervous system also associates
emotions with the immune system.21 Sympathetic
stimulation leads to the release of adrenaline in the
sympathetic nerve terminals and adrenaline secretion
by the adrenal glands. The sympathetic fibers are
closely tied with lymphoid organs, such as the
spleen.25 Adrenaline and noradrenaline decrease the
cellular immune response; the former by increasing
interleukin 6 and the latter via alpha and beta-adren-
ergic receptors.26
Experimental studies have shown that injury to
the brainstem nuclei, rich in noradrenergic neurons,
leads to a reduction in the number of circulating CD4
+ cells.26
Specific areas of the brain that modulate feel-
ings, such as the amygdala and hypothalamus, are
rich in peptides which, when secreted, can affect the
behavior, metabolism and migration of immune cells,
as well as their cytotoxicity and ability to produce
antibodies.26 Negative emotions like depression or
anxiety can affect cells of the immune system and pos-
itively or negatively regulate the release of proinflam-
matory cytokines.21
Communication between the immune system
and the central nervous system is bidirectional, that is,
immune system mediators may act on the central
nervous system, inducing activation of the hypothala-
mic-pituitary axis.25
Approaches that reduce depression symptoms,
including behavioral or pharmacological therapies,
provide an opportunity to positively impact the
immune system. These interventions will possibly
result in the improvement of the physical and mental
health and quality of life of HIV/AIDS patients.27
Even though the effect that cortisol, other hor-
mones and other conditions mediated by the psycho-
logical state of the patient have on immunology has
been described in the literature, it is questionable
whether in cases of HIV patients, in whom there is
depletion of immune cells that are directly attacked by
the virus itself, the emotional and psychological state
of the patient could somehow influence their immune
status.28 The findings of this study suggest that it
could.
Still another possibility to explain these find-
ings would be that FL patients treated would have
greater adherence to ARV therapy. Even if all patients
in the study reported regular use of the same ARV
before and after treatment, strict monitoring of adher-
ence to ARV therapy should be conducted to exclude
or confirm this possibility. However, two studies did
not show statistically significant differences with
regard to treatment adherence before and after FL
treatment.15
The finding of an increase in CD4 cells after
treatment of FL strengthens the recommendation that
this treatment should be always accessible to patients,
integrating the therapeutic options for HIV/AIDS
patients. 
CONCLUSION
Treatment of FL with PMMA implants, which is
today the treatment available in the public healthcare
system in Brazil, showed a positive impact on disease
progression, with a statistically significant increase in
CD4 count after treatment (p = 0.02). This data is
unprecedented in the literature. This increase was
probably due to the positive impact of the treatment
on the emotional and psychological state of the
patients.
In addition to the known benefits of the treat-
ment of FL for the patients’ well being, this new find-
ing corroborates the importance of providing FL treat-
ment in assistance programs for HIV/AIDS patients.
With respect to viral load, there was no statisti-
cally significant change before and after treatment of
FL with PMMA implants (p = 0.67). ❑
REFERENCES
Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of1.
peripheral lipodystrophy, hyperlipidaemia and insulinresistance in patients receiving
HIV protease inhibitors. AIDS. 1998;12:F51-8. 
Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndro-2.
me in HIV infection. AIDS Read. 2000;10:546-50.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST,3.
AIDS e Hepatites Virais. Manual de tratamento da lipoatrofia facial: recomendações
para o preenchimento facial com polimetilmetacrilato em portadores de HIV/AIDS.
Brasília: Ministério da Saúde; 2009. 44 p. (Série A. Normas e Manuais Técnicos).
Behrens GMN, Stoll M, Schimidt RE. Lipodystrophy syndrome in HIV infection: what4.
is it, what causes it and how can it be managed? Drug Saf. 2000;23:57-76.
Cabrero E, Griffa L, Burgos A; HIV Body Physical Changes Study Group. Prevalence5.
and impact of body physical changes in HIV patients treated with highly active antire-
troviral therapy: results from a study on patient and physician perceptions. AIDS
Patient Care STDS. 2010;24:5-13.
Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodefi-6.
ciency virus-infected patients. J Clin Endocrinol Metab. 2002;87:4845-4856.
Baril JG, Junod P, Leblanc R, Dion H, Therrien R, Laplante F, et al. HIV-associated lipo-7.
dystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol.
2005;16:233-43.
Li HY, Silva ACCM, Santos S. Síndrome Lipodistrófica e HIV/AIDS. J Bras Aids.8.
2002;3:23-35.
Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE. The face of HIV and AIDS: can9.
we erase the stigma? AIDS Care. 2008;20:485-7.
Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syn-10.
drome. J Antimicrob Chemother. 2005;56:6-9.
Pujol RM, Domingo P, Xavier-Matias-Guiu, Francia E, Sanbeat MA, Alomar A, et al.11.
HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of
14 cases. J Am Acad Dermatol. 2000;42:193-8.
Baril JG, Junod P, Leblanc R, Dion H, Therrien R, Laplante F, et al. HIV-associated lipo-12.
dystrophy syndrome: A review of clinical aspects. Infect Dis Med Microbiol.
2005;16:233-43.
Narins RS. Minimizing Adverse Events Associated with Poly-L-latic Acid Injection.13.
Dermatol Surg. 2008;34:S100-4.
Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ. A systematic review of14.
permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.
AIDS Patient Care STDS. 2009;23:699-714.
Skeie L, Bugge H, Negaard A, Bergersen BM. Large particle hyaluronic acid for the15.
treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV
Med. 2010;11:170-7. 
Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-16.
lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7:181-5.
Chandra PS, Gandhi C, Satishchandra P, Kamat A, Desai A, Ravi V, et al. Quality of life17.
in HIV subtype C infection among asymptomatic subjects and its association with
CD4 counts and viral loads--a study from South India. Qual Life Res. 2006;15:1597-
605.
Lomar AV, Diament D. Terapia Anti-retroviral. In: Veronesi R, Focaccia R, editores.18.
Tratado de infectologia. São Paulo: Atheneu; 2005. p. 235-41.
Rizzo LV. Imunopatogênese. In: Veronesi R, Focaccia R, editores. Tratado de infecto-19.
logia. São Paulo: Atheneu; 2005. p.138-42.
Ironson G, O`Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, et al.20.
Psychosocial factors predict CD4 and viral load change in men and women with
human immunodeficiency virus in the era of highly active antiretroviral treatment.
Psychosom Med. 2005;67:1013-21.
Kiecolt-Glaser J, McGuire L, Robies TF, Glaser R. Psychoneuroimmunology: psycho-21.
logical influences on immune function and health. J Consult Clin Psychol.
2002;70:537-47.
Antoni MH, Cruess DG, Klimas N, Maher K, Cruess S, Kumar M, et al. Stress22.
Management andImmune System Reconstitution in Symptomatic HIV-Infected Gay
Men Over Time: EffectsonTransitionalNaïve T Cells (CD4+CD45RA+CD29+). Am J
Psychiatry. 2002:159:143-4.
Petrie KJ, Fontanilla I, Thomas MG, Booth RJ, Pennebaker JW. Effect of written emo-23.
tional expression on immune function in patients with human immunodeficiency virus
infection: a randomized trial. Psychosom Med.2004;66:272-5.
Paik IH, Toh KY, Lee C, Kim JJ, Lee SJ. Psychological stress may induce increased24.
humoral and decreased cellular immunity. Behav Med. 2000;26:139-40.
Alves GJ, Palermo-Neto J. Neuroimunomodulação: sobre o diálogo entre os sistemas25.
nervoso e imune. Rev Bras Psquiatr. 2007;29:363-9.
Kooker M. Mind, immunity and health - the science and clinical application of psycho-26.
neuroimmunology. CME. 2008;26:18-20.
O`Connell-Edwards C, Jones DJ. CD4 count and physical symptoms among urban27.
African American mothers with HIV: an examination of the role of optimism and
depressive symptoms. J Clin Psychol Med Settings. 2008;15:322-30.
Ulla S, Remor EA. Psiconeuroimunologia e infecção por HIV: realidade ou ficção?28.
Psicol Reflex Crit. 2002;15:113-9.
How to cite this article: Soares FMG, Costa IMC. HIV-Associated facial lipoatrophy treatment: the impact on the
infection progression assessed by viral loadand CD4 counting. An Bras Dermatol. 2013;88(4):570-7.
MAILING  ADDRESS:
Flávia Machado Gonçalves Soares
SHIS QI 27 conjunto 01 casa 07 - Lago Sul 
71675100 - Brasília - DF
Brazil
E-mail: flaviamachadosoares@gmail.com.br
577 Soares FMG, Costa IMC
An Bras Dermatol. 2013;88(4):570-7.
